Loading…
Loading…
MMED (MiniMed Group, Inc.) is a recent IPO.
It began trading on March 5, 2026, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates. The affected sections are flagged individually so you can tell limited history from missing data.
MMED does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MMED and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MMED and 80,000+ other tickers.
See exactly how MMED's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MMED and 80,000+ other tickers.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
A recent spinoff could pave the way for greater dividend growth.
/PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the composition of its Board of Directors following the
Directors bring expertise across healthcare access, medtech, commercial and manufacturing operations and public-company governance as MiniMed begins its next chapter as an independent company focused on making every day a better day for people with diabetes. NORTHRIDGE, Calif.
GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). "I'm incredibly proud of what MiniMed and Medtronic have accomplished together and the meaningful difference we've made in the lives of people with diabetes," said Geoff Martha, Medtronic Chairman and Chief Executive Officer.
NORTHRIDGE, Calif., Oct. 15, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc ("Medtronic"; NYSE: MDT), marking its first day as a fully independent company.